Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 12, Issue 6, Pages 407-413Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-010-0134-3
Keywords
Myalgia; Ubiquinone coenzyme Q(10); Statins
Categories
Funding
- University Western Australia Medical Research
- Faculty of Medicine, Dentistry and Health Sciences
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
Statins lower cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the biosynthesis of cholesterol. However, severe adverse events, including myalgias and rhabdomyolysis, have been reported with statin treatment. Different mechanisms have been proposed to explain statin-induced myopathy, including reduction of mevalonate pathway products, induction of apoptosis, mitochondrial dysfunction, and genetic predisposition. A decrease in coenzyme Q(10) (CoQ), a product of the mevalonate pathway, could contribute to statin induced myopathy. This article reviews the clinical and biochemical features of statin-induced myopathy, the inter-relationship between statins and the concentration of CoQ in plasma and tissues, and whether there is a role for supplementation with CoQ to attenuate statin-induced myopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available